Table 4 Study characteristics and details
Prophylaxis type | Reported primary outcomes | Reported secondary outcomes | |
|---|---|---|---|
Mun Hon Low et al. 2013 [14] | LMWH (n = 72) NOAC (n = 15) | US | Major |
Takeshi Fuji et al. 2012 [18] | LMWH (n = 66) NOAC (n = 152) | V, C | Minor, major |
Jain et al. 2004 [19] | NP (n = 26) | US, C | None |
Yeo et al. 2016 [20] | MOP (n = 802) | C | None |
Ko et al. 2003[4] | NP (n = 58) | US | None |
Intiyanaravut et al. 2017 [21] | LMWH (n = 25) NP (n = 25) | US, C | Minor, major |
Leizorovicz et al. 2005 [22] | NP (n = 944) | C | Major |
Cho et al. 2013 [15] | MOP (n = 74) | US | Minor, major |
Won et al. 2011 [23] | NP (n = 440) | US | None |
Kim et al. 2015[24] | MOP (n = 874) | V, US | None |
Wang et al. 2004 [16] | LMWH (n = 50) NP (n = 51) | V, C | None |
Pookarnjanamorakot et al. 2004 [25] | NP (n = 67) | V, C | None |
Chen et al. 2008 [26] | NP (n = 78) | V, C | None |
Chin et al. 2009 [27] | LMWH (n = 110) MOP (n = 220) NP (n = 110) | U | Minor, major |